Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1681-1700 of 1,738 trials

Intestinal Failure-Associated Liver Disease: NST-6179 Study

We are testing a new oral medication, NST-6179, for individuals with Intestinal Failure-Associated Liver Disease. The study aims to understand its safety and how it affects liver health.

Intestinal Failure-Associated Liver Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyHepatology

Metastatic Esophagogastric Cancer: MT-302 with CapOx

We are investigating the safety and early effectiveness of a new treatment, MT-302, combined with CapOx chemotherapy for patients with metastatic esophagogastric cancer.

Metastatic Esophagogastric Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Cholangiocarcinoma: Ivosidenib Maintenance Therapy

We are studying whether the drug ivosidenib can help patients with mIDH1 cholangiocarcinoma after standard chemotherapy. The trial will also look at its safety and effects on quality of life.

Cholangiocarcinoma Treatment>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Multiple Sclerosis: THC/CBD Oral Solution

We are studying an oral solution of THC and CBD for people with multiple sclerosis to see if it helps relieve chronic pain and improve other symptoms. This trial compares the treatment to a placebo to assess its effects.

Chronic Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Chronic Cluster Headache: Low-Dose LSD Study

We are investigating whether a low dose of LSD can help reduce the frequency and severity of chronic cluster headaches. This study will assess both its effectiveness and safety compared to a placebo.

Chronic Cluster Headache≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Type 2 Diabetes: RO7795081 Medication Study

We are comparing a new medication, RO7795081, with a placebo and semaglutide in people with type 2 diabetes. The study aims to see how well it controls blood sugar and affects body weight.

Type 2 Diabetes6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinology

Type 2 Diabetes: LY3457263 Treatment Study

We are testing a new medication, LY3457263, in people with type 2 diabetes who are not meeting their blood sugar goals on current treatments. The study will compare its effects to a placebo over 24 weeks.

Type 2 DiabetesEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Influenza Vaccine Study: OVX836

We are testing the OVX836 influenza vaccine in healthy adults to see if it can prevent influenza compared to a placebo. This study will also look at the vaccine's safety and how well it triggers an immune response.

Influenza6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Immune Thrombocytopenia: NVG-2089 Treatment Study

We are testing a new intravenous treatment, NVG-2089, for individuals with Immune Thrombocytopenia. The study aims to evaluate its safety and how well it works in increasing platelet counts.

Immune Thrombocytopenia (ITP)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematology

Bone Health: Everolimus and Exercise for Postmenopausal Women

We are studying if a combination of a medication and resistance training can improve bone formation in healthy postmenopausal women. This research may help in understanding better ways to support bone health.

Healthy Elderly Women3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementGynecology and ObstetricsOrthopedics and Traumatology

Diabetic Macular Edema: BI 1815368 Study

We are testing whether the oral medication BI 1815368 can improve vision in people with diabetic macular edema. The study will also look at the safety of this treatment over time.

Diabetic Macular Edema6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteEndocrinologyOphthalmology

Advanced Solid Tumors: EIK1004 Treatment Study

We are testing a new treatment called EIK1004 for people with advanced solid tumors to see how safe it is and if it may help reduce tumor activity. This study will help us understand the best dose and its effects.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Cemiplimab for Advanced Adrenocortical Cancer

We are studying whether cemiplimab can help patients with advanced adrenocortical cancer maintain their health after initial treatment. This trial focuses on those who have not experienced disease progression.

Adrenocortical Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Health: Orticumab for Inflammation After Heart Attack

We are studying whether orticumab can reduce inflammation in people who have had a heart attack and show elevated coronary inflammation. The trial will also evaluate the safety of this treatment.

Heart Attack6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine

Chronic Obstructive Pulmonary Disease: AZD6793 Tablets

We are investigating whether AZD6793 can help reduce flare-ups in adults with moderate to very severe COPD. The study will also look at its effects on lung function and overall health.

Chronic Obstructive Pulmonary Disease (COPD)6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePulmonology

Chronic Obstructive Pulmonary Disease: Verekitug Study

We are investigating whether Verekitug can help people with moderate-to-severe COPD manage their symptoms and improve lung function. The study will also assess the safety and overall impact on quality of life.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Glioblastoma: Intraoperative Photodynamic Therapy with Pentalafen®

We are studying a new light-based treatment for adults with grade IV glioblastoma during surgery. The goal is to evaluate its safety and how well it works in reducing tumor response.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteGastroenterologyOncology

Nasopharyngeal Carcinoma: Imaging Study with [68Ga]Ga-DOTA-TOC

We are exploring a new imaging method to assess tumors in patients with EBV-related nasopharyngeal carcinoma. This study aims to improve treatment choices by understanding how the tumor responds to therapy.

Nasopharyngeal Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology